Dr. Howard Smith Oncall

  Vidcast:  https://youtu.be/h_6iJu3pBEk   Between 78 to 92% of  lung cancers in non-smokers may be effectively treated with drugs already approved by the FDA.  Oncologists and geneticists at the Washington University School of Medicine in St. Louis compared genetic tumor data from 164 never-smoking lung cancer patients with that from 299 smokers.   The analyses showed that lung cancers occurring in non-smokers were 1.5 to nearly 2 times more likely to be controlled with currently existing and approved medicinals compared with tumors found in the smoking population.  Passive smoke also plays role in non-smoker cancer, since 5.9% of the never-smoked tumor samples had mutation signatures suggesting smoke exposure.   This study shows the importance of obtaining sufficient tumor cell material in biopsies in order to perform complete genomic analyses.   https://ascopubs.org/doi/10.1200/JCO.21.01691   #lungcancer #smoking #neversmoking #genome